—m‘

< ŠàŽ¡—Â̂½‚߂̖Ɖu’²ß–ò >

Immunomodulating Drugs for the Treatment of Cancer

’˜ŽÒ : A.A.A.Chanan-Khan
o”ÅŽÐ : LIPPINCOTT WILLIAMS & WILKINS
ISBN : 978-1-60547-333-8
ƒy[ƒW” : 299pp.(208illus.)
o”Å”N : 2011”N

ÝŒÉ‚È‚µ

’艿17,269‰~(–{‘Ì15,990‰~ { Å)

  • ƒIƒ“ƒ‰ƒCƒ“
  • ¤•ià–¾

Table of Contents
Part 1: INTRODUCTION

1: Introduction to the Immunomodulatory Agents for the Treatment of Malignant Conditions
Part 2: PRECLINICAL DEVELOPMENT
2: The Mechanism of Action of the Immunomodulating Drugs (IMiDs) Compounds
Part 3: CLINICAL DEVELOPMENT
3: Overview: Clinical Impact of IMiDs in Oncology
4: Thalidomide for Relapsed or Refractory Myeloma
5: Role of IMiDs as Initial Therapy for Multiple Myeloma
6: Role of Immunomodulatory Drugs for the Treatment of Newly Diagnosed Multiple Myeloma in Elderly Patients
7: IMiDs as Maintenance Therapy in Multiple Myeloma
8: Lenalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
9: IMiDs and Stem Cell Transplantation in Multiple Myeloma
10: IMiDs in Waldenstrom's Macroglobulinemia
11: Lenalidomide for the Treatment of Myelodysplastic Syndrome
12: Thalidomide and Lenalidomide for the Treatment of Primary Myelofibrosis
13: Immunomodulatory Drugs for the Treatment of Chronic Lymphocytic Leukemia
14: Lenalidomide in Combination with Other Novel Agents: A New Diimension in Myeloma Therapeutics
15: Lenalidomide for Non-Hodgkin's Lymphoma
16: Clinical Efficacy of Immunomodulatory Drugs in Amyloidosis
17: Immunomodulating Drugs for the Treatment of Prostate Cancer
18: Pomalidomide in Cancer Therapy
Part 4: COMPLICATIONS
19: IMiDs-Associated Toxicities and Their Management
20: Toxicity Associated with the Immunomodulating Agents in Patients with Chronic Lymphocytic Leukemia
Index